Hemostasis Today

July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Novi Yanti Sari: When MPNs Affect the Heart
Jul 26, 2026, 16:26

Novi Yanti Sari: When MPNs Affect the Heart

Novi Yanti Sari, Lecturer at Universitas Pelita Harapan, shared a post on LinkedIn about a recent article by Orly Leiva et al, published in Journal of the American College of Cardiology, adding:

”Beyond thrombosis: what cardiovascular complications should we look for in patients with MPN?

This review highlights that the CV burden extends beyond arterial & venous thrombosis:

  • HF may be more prevalent in MPNs than in general population, with worse HF-specific outcomes reported in myelofibrosis
  • Traditional CV risk factors are less common in these patients, suggesting a distinct HF phenotype
PH is common and may be pre-capillary, post-capillary or combined, requiring careful haemodynamic evaluation. Echo First is the recommended screening tool, with RHC for definitive diagnosis
  • PH screening should be considered in patients with myelofibrosis, long-standing MPN, signs of disease progression and cardiomegaly
Emerging data suggest that both HF and PH may be associated with adverse cardiovascular outcomes and hematologic progression in MPN, highlighting potential shared pathophysiology such as chronic inflammation and JAK/STAT pathway activation.”

Title: Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review

Authors: Orly Leiva, Olivia Liu, Anthony Kanelidis, Stanley Swat, Leo Gozdecki, Mark Belkin, Jonathan Grinstein, Sara Kalantari, Gene Kim, Jeanne DeCara, Ben Chung, Anand Patel, Olatoyosi Odenike, Eric H. Yang, Michelle Bloom, Jose Alvarez-Cardona, Joan How, Gabriela Hobbs.

Novi Yanti Sari: When MPNs Affect the Heart

Stay updated on all scientific advances with Hemostasis Today.